Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07658222 · ClinicalTrials.gov registry record
Prospective Investigation of Cirrhotic Cardiomyopathy in Humans
A clinical trial, sponsored by Vanderbilt University Medical Center.
- Recruiting
- Registry status
- 440
- Enrollment target
NCT07658222: Recruiting study, sponsored by Vanderbilt University Medical Center.
NCT07658222 is a clinical trial that is actively recruiting participants, run by Vanderbilt University Medical Center. The registered enrollment target is 440 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07658222 is actively recruiting participants, sponsored by Vanderbilt University Medical Center.
- RECRUITING
- Registry status
- 440 participants
- Enrollment target
Study Summary
Cirrhotic Cardiomyopathy (CCM) is a recognized complication of cirrhosis, but understudied despite recent retrospective data suggesting it may be common, affecting one in three patients with decompensated cirrhosis, and associated with significantly increased risk of death and adverse hepatic and cardiac events. Moreover, evidence from preclinical models and children suggest elevated bile acids in the blood may contribute to CCM, but data from adults with cirrhosis are scarce. Therefore, we are conducting the first contemporary prospective multi-center investigation of CCM in adults in the USA to define CCM risk factors and impact on outcomes while deepening understanding of the role of bile acids in development of this disease.
Primary Outcome
Death from any cause occurring during the follow-up period. Mortality status will be ascertained through review of medical records.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 440 participants |
| Start Date | 2026-01-20 |
| Est. Completion | 2030-06-30 |
What NCT07658222 shows while recruiting
NCT07658222 is an observational study that tracks outcomes without assigning an intervention. The registered 440 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT07658222 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07658222 about?
NCT07658222 is a clinical study titled "Prospective Investigation of Cirrhotic Cardiomyopathy in Humans". Cirrhotic Cardiomyopathy (CCM) is a recognized complication of cirrhosis, but understudied despite recent retrospective data suggesting it may be common, affecting one in three patients with decompensated cirrhosis, and associated with significantly increased risk of death and adverse hepatic and ca...
What is the current status of trial NCT07658222?
This trial is currently recruiting. The enrollment target is 440 participants. The study started on 2026-01-20. Estimated completion is 2030-06-30.
Who is sponsoring clinical trial NCT07658222?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05114538 · 440 participants · NA
Improving the Part C Early Intervention Service Delivery System for Children with ASD
- NCT05117619 · 440 participants · NA
The HOME Program for Individuals With Traumatic Brain Injury and Family Members
- NCT05602194 · 440 participants · Phase 3
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
- NCT05624879 · 440 participants · NA
Accelerated Resolution Therapy for Early Maladaptive Grief
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI